Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021
Sep 14, 2021
REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments, announced today that Mr. Ofer Haviv, Evogene’s President and CEO, will be interviewed in a “Fireside Chat” at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021. Mr. Haviv’s interview will focus on Evogene’s disruptive technologies; its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries and will take place on Tuesday September 28, 2021, at 10:40 am, EST and will be available through the following webcast link: https://wsw.com/webcast/cantor12/evgn/2086560.
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at firstname.lastname@example.org or through the conference’s online meeting platform.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit www.evogene.com.
Evogene Investor Contact:
Aviva Banczewski / Rivka Neufeld
Investor Relations and Public Relations Manager
US Investor Relations:
T: +1 646-653-7030
T: +1 646-653-7035